Document and Entity Information
Document and Entity Information | Mar. 15, 2022 |
Cover [Abstract] | |
Security Exchange Name | NASDAQ |
Amendment Flag | true |
Entity Central Index Key | 0001832415 |
Document Type | 8-K/A |
Document Period End Date | Mar. 15, 2022 |
Entity Registrant Name | BETTER THERAPEUTICS, INC. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-39864 |
Entity Tax Identification Number | 85-3472546 |
Entity Address, Address Line One | 548 Market Street #49404 |
Entity Address, City or Town | San Francisco |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94104 |
City Area Code | (415) |
Local Phone Number | 887-2311 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock |
Trading Symbol | BTTX |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Amendment Description | This Amendment No. 1 on Form 8-K/A (“Form 8-K/A”) amends the Current Report on Form 8-K of Better Therapeutics, Inc., a Delaware corporation (the “Company”), filed on March 15, 2022 (the “Original 8-K”). This Form 8-K/A is being filed solely to amend Exhibit 99.2 to the Original 8-K to correct an error in the chart depicted on the slide titled “Dose Response of nCBT.” No other changes have been made to the Original 8-K or the exhibits thereto. |